Nonalcoholic fatty liver disease: an update.

IF 3.8 3区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Current opinion in lipidology Pub Date : 2023-06-01 DOI:10.1097/MOL.0000000000000874
Giorgio Bedogni, Francesco Palmese, Francesco Giuseppe Foschi
{"title":"Nonalcoholic fatty liver disease: an update.","authors":"Giorgio Bedogni,&nbsp;Francesco Palmese,&nbsp;Francesco Giuseppe Foschi","doi":"10.1097/MOL.0000000000000874","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>We discuss two recent controversial issues in the research field of fatty liver: the proposal to replace nonalcoholic fatty liver disease (NAFLD) with metabolically associated fatty liver disease (MAFLD) and the suggestion to extend to primary care the noninvasive testing for liver fibrosis that was developed for secondary care.</p><p><strong>Recent findings: </strong>There is preliminary evidence that MAFLD-only patients are at greater risk of fibrosis than NAFLD-only patients. There are a large number of false positives associated with the downshift of noninvasive testing for liver fibrosis from secondary to primary care.</p><p><strong>Summary: </strong>More studies are needed to compare the MAFLD and NAFLD operational definitions. Noninvasive testing of liver fibrosis also needs further evaluation before it can be used in primary care or in the general population.</p>","PeriodicalId":11109,"journal":{"name":"Current opinion in lipidology","volume":"34 3","pages":"114-118"},"PeriodicalIF":3.8000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in lipidology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MOL.0000000000000874","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

Purpose of review: We discuss two recent controversial issues in the research field of fatty liver: the proposal to replace nonalcoholic fatty liver disease (NAFLD) with metabolically associated fatty liver disease (MAFLD) and the suggestion to extend to primary care the noninvasive testing for liver fibrosis that was developed for secondary care.

Recent findings: There is preliminary evidence that MAFLD-only patients are at greater risk of fibrosis than NAFLD-only patients. There are a large number of false positives associated with the downshift of noninvasive testing for liver fibrosis from secondary to primary care.

Summary: More studies are needed to compare the MAFLD and NAFLD operational definitions. Noninvasive testing of liver fibrosis also needs further evaluation before it can be used in primary care or in the general population.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
非酒精性脂肪性肝病:最新进展
综述目的:我们讨论了脂肪肝研究领域最近两个有争议的问题:用代谢相关脂肪性肝病(MAFLD)代替非酒精性脂肪性肝病(NAFLD)的建议,以及将用于二级保健的肝纤维化无创检测扩展到初级保健的建议。近期发现:有初步证据表明,仅nafld患者比仅nafld患者发生纤维化的风险更大。有大量的假阳性与肝纤维化的无创检测从二级保健降至初级保健有关。总结:需要更多的研究来比较MAFLD和NAFLD的操作定义。肝纤维化的无创检测在用于初级保健或普通人群之前还需要进一步评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current opinion in lipidology
Current opinion in lipidology 医学-内分泌学与代谢
CiteScore
6.70
自引率
4.50%
发文量
64
审稿时长
6-12 weeks
期刊介绍: With its easy-to-digest reviews on important advances in world literature, Current Opinion in Lipidology offers expert evaluation on a wide range of topics from six key disciplines including nutrition and metabolism, genetics and molecular biology, and hyperlipidaemia and cardiovascular disease. Published bimonthly, each issue covers in detail the most pertinent advances in these fields from the previous year. This is supplemented by a section of Bimonthly Updates, which deliver an insight into new developments at the cutting edge of the disciplines covered in the journal.
期刊最新文献
Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit? From clinical development to real-world outcomes with inclisiran. Oral agents for lowering lipoprotein(a). Universal screening for familial hypercholesterolaemia: how can we maximise benefits and minimise potential harm for children and their families? A contemporary snapshot of familial hypercholesterolemia registries.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1